CAMBRIDGE, Mass.–(BUSINESS WIRE)–Metamark Genetics, Inc. (“Metamark” or the “Company”), a leader in commercializing high-value urologic oncology products, today announced that a study published in The Oncologist demonstrates that use of its novel proteomic prognostic test ProMark®, for early-stage prostate cancer, is likely to result in more cost-effective care than the National …